Stock Taper
Organon & Co. develops global health solutions across women’s health, biosimilars, oncology, cardiovascular, respiratory, dermatology, and other therapies, primarily selling to healthcare providers, hospitals, and government agencies.

Organon's flagship long-acting, reversible contraceptive implant, placed under the upper arm and effective for up to three years, is a key product driving the company's women's health portfolio.
| Map | REGION | Q3-2025 | Q4-2025 | Q1-2026 | Q2-2026 |
|---|---|---|---|---|---|
![]() | NonUS | — | — | $1.1B | $1.16B ▲ |
![]() | Europe And Canada | $417M | $406M ▼ | $412M ▲ | $432M ▲ |
![]() | UNITED STATES | $406M | $372M ▼ | $358M ▼ | $414M ▲ |
![]() | Latin America Middle East Russia And Africa | $286M | $261M ▼ | $247M ▼ | $269M ▲ |
![]() | AsiaPacific and Japan | $251M | $248M ▼ | $226M ▼ | $232M ▲ |
![]() | CHINA | $219M | $202M ▼ | $194M ▼ | $208M ▲ |
![]() | Other Countries | $23M | $18M ▼ | $23M ▲ | $19M ▼ |
Overall rating: B
| PEER | PRICE | |
|---|---|---|
GRDN | $37.06 | COMPARE |
NUVB | $6.66 | COMPARE |
HRMY | $39.21 | COMPARE |
MD | $26.61 | COMPARE |
AUPH | $16.29 | COMPARE |
ALVO | $4.95 | COMPARE |
PAHC | $37.67 | COMPARE |
TLRY | $4.59 | COMPARE |